Abril - 2017

14 / 103

Hanna and Pimentel
298 Rev Assoc Med Bras 2017; 63(4):293-298
12. Wilt TJ, Brawer MK. The Prostate Cancer Intervention Versus Observation
Trial: a randomized trial comparing radical prostatectomy versus expectant
management for the treatment of clinically localized prostate cancer. J Urol.
1994; 152(5 Pt 2):1910-4.
13. Raldow AC, Zhang D, Chen MH, Braccioforte MH, Moran BJ, D’Amico AV.
Risk group and death from prostate cancer: implications for active
surveillance in men with favorable intermediate-risk prostate cancer. JAMA
Oncol. 2015; 1(3):334-40.
14. Becerra Bachino V, Cots F, Guedea F, Pera J, Boladeras A, Aguiló F, et al.;
Grupo Multicéntrico Español de Cáncer de Próstata Organoconfinado.
[Cost comparison of three treatments for localized prostate cancer in Spain:
radical prostatectomy, prostate brachytherapy and external 3D conformal
radiotherapy]. Gac Sanit. 2011; 25(1):35-43.
15. Crook JM, Gomez-Iturriaga A, Wallace K, Ma C, Fung S, Alibhai S, et al.
Comparison of health-related quality of life 5 years after SPIRIT: Surgical
Prostatectomy Versus Interstitial Radiation Intervention Trial. J Clin Oncol.
2011; 29(4):362-8.
16. Giberti C, Chiono L, Gallo F, Schenone M, Gastaldi E. Radical retropubic
prostatectomy versus brachytherapy for low-risk prostatic cancer: a
prospective study. World J Urol. 2009; 27(5):607-12.
17. Zelefsky MJ, Wallner KE, Ling CC, Raben A, Hollister T, Wolfe T, et al.
Comparison of the 5-year outcome and morbidity of three-dimensional
conformal radiotherapy versus transperineal permanent iodine-125 implantation
for early-stage prostatic cancer. J Clin Oncol. 1999; 17(2):517-22.
18. Grimm P, Billiet I, Bostwick D, Dicker AP, Frank S, Immerzeel J, et al.
Comparative analysis of prostate-specific antigen free survival outcomes
for patients with low, intermediate and high risk prostate cancer treatment
by radical therapy. Results from the Prostate Cancer Results Study Group.
BJU Int. 2012; 109(Suppl 1):22-9.
19. Davis BJ, Horwitz EM, Lee R, Crook JM, Stock RG, Merrick GS, et al.;
American Brachytherapy Society. American Brachytherapy Society consensus
guidelines for transrectal ultrasound-guided permanent prostate
brachytherapy. Brachytherapy. 2012; 11(1):6-19.
20. American Urological Association. Guideline for the management of clinically
localized prostate cancer (2007) [cited 2015 May]. Available from: https://
21. Corner C, Rojas AM, Bryant L, Ostler P, Hoskin P. A phase II study of high-
-dose-rate afterloading brachytherapy as monotherapy for the treatment of
localized prostate cancer. Int J Radiat Oncol Biol Phys. 2008; 72(2):441-6.
22. Kukiełka AM, D ąbrowski T, Walasek T, Olchawa A, Kudzia R, Dybek D.
High-dose-rate brachytherapy as a monotherapy for prostate cancer – Sin-
gle-institution results of the extreme fractionation regimen. Brachytherapy.
2015; 14(3):359-65.
23. Tselis N, Tunn UW, Chatzikonstantinou G, Milickovic N, Baltas D, Ratka
M, et al. High dose rate brachytherapy as monotherapy for localised prostate
cancer: a hypofractionated two-implant approach in 351 consecutive patients.
Radiat Oncol. 2013; 8:115.
24. Yamada Y, Rogers L, Demanes JD, Morton G, Prestidge BR, Pouliot J, et al.
American Brachytherapy Society consensus guidelines for high-dose-rate
prostate brachytherapy. Brachytherapy. 2012; 11(1):20-32.
25. Lee RW, Bae K, Lawton C, Gillin M, Morton G, Firat S, et al. Late toxicity
and biochemical recurrence after external-beam radiotherapy combined
with permanent-source prostate brachytherapy. Analysis of Radiation
Therapy Oncology Group Study 0019. Cancer. 2007; 109(8):1506-12.
26. Sylvester JE, Grimm PD, Blasko JC, Millar J, Orio PF 3rd, Skoglund S, et al.
15-year biochemical relapse free survival in clinical Stage T1-T3 prostate
cancer following combined external beam radiotherapy and brachytherapy;
Seattle experience. Int J Radiat Oncol Biol Phys. 2007; 67(1):57-64.
27. Martinez A, Gonzalez J, Spencer W, Gustafson G, Kestin L, Kearney D, et al.
Conformal high dose rate brachytherapy improves biochemical control and
cause specific survival in patients with prostate cancer and poor prognostic
factors. J Urol. 2003; 169(3):974-80.
28. Kim S, Moore DF, Shih W, Lin Y, Li H, Shao YH, et al. Severe genitourinary
toxicity following radiation therapy for prostate cancer — how long does it
last? J Urol. 2012; 189(1):116-21.
29. Alicikus ZA, Yamada Y, Zhang Z, Pei X, Hunt M, Kollmeier M, et al. Ten-
-year outcomes of high-dose, intensity-modulated radiotherapy for locali-
zed prostate cancer. Cancer. 2011; 117(7):1429-37.
30. Mohammed N, Kestin L, Ghilezan M, Krauss D, Vicini F, Brabbins D, et al.
Comparison of acute and late toxicities for three modern high-dose radiation
treatment techniques for localized prostate cancer. Int J Radiat Oncol Biol
Phys. 2012; 82(1):204-12.
31. Sanda MG, Dunn RL, Michalski J, Sandler HM, Northouse L, Hembroff L,
et al. Quality of life and satisfaction with outcome among prostate-cancer
survivors. N Engl J Med. 2008; 358(12):1250-61.
32. Komiya A, Fujiuchi Y, Ito T, Morii A, Yasuda K, Watanabe A, et al. Early qua-
lity of life outcomes in patients with prostate cancer managed by high-do-
se-rate brachytherapy as monotherapy. Int J Urol. 2013; 20(2):185-92.